Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Avalo Therapeutics, Inc. (CERC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates"
11/07/2022 8-K Quarterly results
Docs: "Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates"
08/04/2022 8-K Quarterly results
Docs: "Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates"
05/05/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates"
08/02/2021 8-K Quarterly results
Docs: "Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates"
11/09/2020 8-K Quarterly results
Docs: "Third Quarter Highlights and Program Updates"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/11/2020 8-K Quarterly results
11/14/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "Cerecor Reports Second Quarter 2019 Results -Positive Final Results with CERC-301 in nOH -First Patient Enrolled in CDG FIRST Trial - FDA Acceptance of IND Application of CERC-802"
05/09/2019 8-K Quarterly results
Docs: "Cerecor Reports First Quarter 2019 Results - Positive interim results from the Phase l study of CERC-301 in nOH -Positive results from Phase I Safety Data for CERC-801 in Healthy Volunteers"
03/18/2019 8-K Quarterly results
Docs: "Cerecor Reports Fourth Quarter and Full Year 2018 Results -Significant Advancement in Pipeline and Regulatory Milestones -Meets Increased 2018 Revenue Guidance -Announces Net Revenue Guidance of $20-22 Million for 2019"
11/13/2018 8-K Quarterly results
Docs: "Cerecor Reports Third Quarter 2018 Results"
08/09/2018 8-K Quarterly results
Docs: "Cerecor Reports Second Quarter 2018 Financial Results BALTIMORE — — August 9, 2018 — Cerecor Inc. , an integrated biopharmaceutical company focused on pediatric healthcare and developing innovative therapies that make a difference in the lives of patients today announced financial results for the second quarter and first half of 2018."
11/06/2017 8-K Quarterly results
Docs: "Cerecor Inc. Reports Third Quarter 2017 Financial Results Current cash and escrowed cash receivables in excess of $27 million"
08/14/2017 8-K Quarterly results
Docs: "Asset Purchase Agreement, by and among Cerecor Inc. and Janssen Pharmaceuticals, Inc",
"Cerecor Inc. Reports Second Quarter 2017 Financial Results",
"Cerecor Announces Divestiture of CERC-501 to Janssen Pharmaceuticals, Inc. BALTIMORE — — — Cerecor Inc. , a biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that it has sold to Janssen Pharmaceuticals, Inc. all of its rights to CERC-501 for initial gross proceeds of $25 million, of which $3.75 million was deposited into a 12-month escrow to secure future indemnification obligations to Janssen, as well as a potential future $20 million regulatory milestone payment. CERC-501 is a potent and selective oral kappa opioid receptor antagonist that Cerecor has been developing as an adjunctive treatment of major depressive disorder and for substance use disorders. CERC-501 has been observed to have activity ...",
"Cerecor Inc. Announces Retirement of Dr. Uli Hacksell as President and Chief Executive Officer"
05/09/2017 8-K Form 8-K - Current report
03/14/2017 8-K Form 8-K - Current report
11/08/2016 8-K Quarterly results
Docs: "Cerecor Inc. Reports Third Quarter 2016 Financial Results"
08/15/2016 8-K Quarterly results
Docs: "Cerecor Inc. Reports Second Quarter 2016 Financial Results"
03/23/2016 8-K Quarterly results
Docs: "Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015 BALTIMORE——March 23, 2016— Cerecor Inc. , a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced its financial results for the fourth quarter and year ended December 31, 2015. “Cerecor made significant strides in the last year in advancing its drug candidates,” said Uli Hacksell, President and CEO of Cerecor. “We initiated a Phase 2 study of CERC-301 and bolstered our clinical pipeline with the acquisition of CERC-501, for which we initiated a Phase 2 study in early 2016. We also strengthened our cash position by raising $26 million in our initial public offering in October of last..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy